Summary
Multiple claims were evaluated against provided label excerpts, but several statements are not supported or are outside the provided labeling (e.g., generic substitution/number of manufacturers/bioequivalence wording). Additionally, some claims include information not present in the excerpts (e.g., 'Revatio generic' meaning).
Category Scores
Accurate Statements
Sildenafil is the same active ingredient across indications.
Label mechanism section states: “Sildenafil is an inhibitor of cGMP specific PDE-5…”. The provided excerpts consistently describe sildenafil as the active drug used in PAH.
Products may differ in formulation, strength, dosing instructions, and labeling for the condition being treated.
The excerpts show REVATIO has multiple dosage forms/strengths with different administration routes (tablets vs oral suspension vs injection) and route-specific dosing instructions.
Unsupported Statements
Revatio is the brand name of sildenafil oral tablets.
The provided excerpts label REVATIO as a sildenafil product, but they do not explicitly state 'brand name of sildenafil oral tablets' as phrased.
A 'Revatio generic' typically means a generic sildenafil product sold under its drug name rather than the brand.
The provided label excerpts do not address how 'Revatio generic' is used or interpreted.
Generic sildenafil products should contain sildenafil, not a different PDE-5 inhibitor.
The provided label excerpts do not discuss generic product composition requirements.
The strength of generic sildenafil labeled as 'Revatio' should match the strength that was prescribed.
The provided label excerpts do not discuss generic-strength matching or substitution labeling practices.
Generic sildenafil for pulmonary arterial hypertension should match the indication and directions on the specific product.
The provided label excerpts do not discuss generic product indication/directions matching or interchangeability.
For generic approval of sildenafil products, generic manufacturers must show the product is bioequivalent to the reference drug.
The provided label excerpts do not describe generic approval requirements or bioequivalence obligations.
Bioequivalence means the same active ingredient and comparable rate and extent of absorption.
The provided label excerpts do not define bioequivalence.
Depending on location, several generic manufacturers may sell sildenafil at the same labeled strength.
The provided label excerpts do not discuss numbers of manufacturers by location or market availability.
Substitution rules and whether pharmacists can automatically substitute depend on local law and prescription wording.
The provided label excerpts do not address substitution practices or laws.
Contradictions
Low
AI Statement
The strength of generic sildenafil labeled as 'Revatio' should match the strength that was prescribed.
Label Reference
2 DOSAGE AND ADMINISTRATION; 3 DOSAGE FORMS AND STRENGTHS
Important Omissions
If evaluating generic use/switching claims, the label excerpts provided do not include sections on generic substitution, interchangeability, or pharmacy substitution policies; evaluating these would require that labeling context.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most claims are informational about generic labeling/substitution and generic approval concepts not supported by the provided label excerpts; they do not directly assert an incorrect dosing regimen for REVATIO. However, unsupported substitution/bioequivalence/switching claims could mislead if treated as labeling-authoritative.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Review
Primary Issue
Several statements are not supported by the provided FDA label excerpts, especially those about generics, bioequivalence definitions, substitution rules, and manufacturer/market behavior.
Suggested Improvement
Restrict claims to what the provided label excerpts support (e.g., REVATIO is sildenafil citrate; PAH indication; specific route/dose regimens and dose forms). Remove or rephrase unsupported statements about generic substitution, bioequivalence requirements, or local pharmacy substitution laws unless those are explicitly present in the provided labeling.